Dorzolamide/timolol fixed combination effective for normal-tension glaucoma
Researchers have found dorzolamide/timolol fixed combination to be an effective IOP-lowering agent for patients with normal-tension glaucoma.
A prospective, open-label, multicenter study included 37 patients with treatment-naïve, normal-tension glaucoma who received dorzolamide/timolol fixed combination therapy for 12 weeks to reduce IOP. For each visit, the researchers measured patients’ IOP at 9 a.m. prior to the administration of dorzolamide/timolol fixed combination therapy; IOP was then measured again at 11 a.m. and 5 p.m. IOP was also measured at 1 p.m. and 3 p.m. at the 12-week follow-up.
At the time of peak drug effect (11 a.m.), the researchers noted a significant reduction in IOP from baseline at the 12-week follow-up (11.9 mm Hg vs. 15.6 mm Hg; P < .0001). A significant IOP reduction was also observed at trough drug effect at 9 a.m. and 8 hours following drug administration at 5 p.m. (P < .0001).
The most commonly reported adverse event was eye irritation (59.5%) and ocular hyperemia (16.2%). However, the eye irritations appeared to be mild in intensity, according to the researchers.
Disclosure: Park and Kim have received honoraria from Alcon Laboratories, Allergan, Merck and Pfizer, as well as investigator fees from MSD Korea Ltd. Merck designed and sponsored the study.